comparemela.com

Latest Breaking News On - Johnf paolini - Page 1 : comparemela.com

Kiniksa Pharmaceuticals (KNSA) Announces Development Indication for Abiprubart

Kiniksa Pharmaceuticals (KNSA) Announces Development Indication for Abiprubart
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Wedbush Weighs in on Kiniksa Pharmaceuticals, Ltd s Q1 2025 Earnings (NASDAQ:KNSA)

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) – Equities research analysts at Wedbush issued their Q1 2025 earnings per share (EPS) estimates for Kiniksa Pharmaceuticals in a research note issued to investors on Wednesday, February 28th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings of ($0.17) per share for the quarter. Wedbush […]

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Sets New 1-Year High at $20 94

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Free Report) shares hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $20.94 and last traded at $20.83, with a volume of 197612 shares traded. The stock had previously closed at $20.16. Analyst Ratings Changes KNSA has been the topic of […]

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Reaches New 1-Year High at $20 94

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Free Report)’s stock price hit a new 52-week high during trading on Tuesday . The stock traded as high as $20.94 and last traded at $20.83, with a volume of 197612 shares traded. The stock had previously closed at $20.16. Analyst Upgrades and Downgrades A number of research analysts […]

Q1 2025 Earnings Estimate for Kiniksa Pharmaceuticals, Ltd (NASDAQ:KNSA) Issued By Wedbush

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) – Stock analysts at Wedbush issued their Q1 2025 EPS estimates for Kiniksa Pharmaceuticals in a research report issued on Wednesday, February 28th. Wedbush analyst D. Nierengarten forecasts that the company will post earnings per share of ($0.17) for the quarter. Wedbush currently has a “Outperform” rating and […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.